1. Crawford PC, Dubovi EJ, Castleman WL, et al. Transmission of equine influenza virus to dogs. Science. 2005; 310:482–485.
2. Song D, Kang B, Lee C, et al. Transmission of avian influenza virus (H3N2) to dogs. Emerg Infect Dis. 2008; 14:741–746.
3. Center for Disease Control and Prevention. Key facts about canine influenza (dog flu). Atlanta, GA: Center for Disease Control and Prevention;2019.
4. Song DS, An DJ, Moon HJ, et al. Interspecies transmission of the canine influenza H3N2 virus to domestic cats in South Korea, 2010. J Gen Virol. 2011; 92(Pt 10):2350–2355.
5. Kim H, Song D, Moon H, et al. Inter- and intraspecies transmission of canine influenza virus (H3N2) in dogs, cats, and ferrets. Influenza Other Respir Viruses. 2013; 7:265–270.
6. Lyoo KS, Kim JK, Kang B, et al. Comparative analysis of virulence of a novel, avian-origin H3N2 canine influenza virus in various host species. Virus Res. 2015; 195:135–140.
7. Sohrab SS, Suhail M, Kamal MA, Husen A, Azhar EI. Recent development and future prospects of plant-based vaccines. Curr Drug Metab. 2017; 18:831–841.
8. Pillet S, Aubin E, Trepanier S, et al. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol. 2016; 168:72–87.
9. Takeyama N, Kiyono H, Yuki Y. Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Ther Adv Vaccines. 2015; 3:139–154.
10. Medicago. Pipeline. Quebec City: Medicago;2019.
11. Mappbio. Product development. San Diego, CA: Mapp Biopharmaceautical;2019.
12. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000; 69:531–569.
13. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods. 2006; 40:60–65.
14. D'Aoust MA, Lavoie PO, Couture MM, et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J. 2008; 6:930–940.
15. Cummings JF, Guerrero ML, Moon JE, et al. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults. Vaccine. 2014; 32:2251–2259.
16. Chichester JA, Jones RM, Green BJ, et al. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses. 2012; 4:3227–3244.
17. Shoji Y, Farrance CE, Bautista J, et al. A plant-based system for rapid production of influenza vaccine antigens. Influenza Other Respir Viruses. 2012; 6:204–210.
18. Landry N, Pillet S, Favre D, et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol. 2014; 154:164–177.
19. Diamos AG, Rosenthal SH, Mason HS. 5′ and 3′ untranslated regions strongly enhance performance of geminiviral replicons in Nicotiana benthamiana leaves. Front Plant Sci. 2016; 7:200.
20. Huang Z, Chen Q, Hjelm B, Arntzen C, Mason H. A DNA replicon system for rapid high-level production of virus-like particles in plants. Biotechnol Bioeng. 2009; 103:706–714.
21. Huang Z, Phoolcharoen W, Lai H, et al. High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol Bioeng. 2010; 106:9–17.
22. Kapusta J, Modelska A, Figlerowicz M, et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 1999; 13:1796–1799.
23. Pniewski T, Kapusta J, Bociag P, et al. Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation. J Appl Genet. 2011; 52:125–136.
24. Govea-Alonso DO, Rubio-Infante N, Garcia-Hernandez AL, et al. Immunogenic properties of a lettuce-derived C4(V3)6 multiepitopic HIV protein. Planta. 2013; 238:785–792.
25. Lai H, He J, Engle M, Diamond MS, Chen Q. Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. Plant Biotechnol J. 2012; 10:95–104.
26. Santi L, Batchelor L, Huang Z, et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine. 2008; 26:1846–1854.
27. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A. 2017; 114:12578–12583.
28. An Y, Parsons LM, Jankowska E, Melnyk D, Joshi M, Cipollo JF. N-glycosylation of seasonal influenza vaccine hemagglutinins: implication for potency testing and immune processing. J Virol. 2019; 93:e01693–e01618.
29. Gupta R, Jung E, Brunak S. Prediction of N-glycosylation sites in human proteins. NetNGlyc 1.0 Server. Lyngby: DTU Bioinformatics;2004.
30. Kalthoff D, Giritch A, Geisler K, et al. Immunization with plant-expressed hemagglutinin protects chickens from lethal highly pathogenic avian influenza virus H5N1 challenge infection. J Virol. 2010; 84:12002–12010.
31. Phoolcharoen W, Dye JM, Kilbourne J, et al. A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. Proc Natl Acad Sci U S A. 2011; 108:20695–20700.
32. Chen Q, He J, Phoolcharoen W, Mason HS. Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants. Hum Vaccin. 2011; 7:331–338.
33. Kwon KC, Nityanandam R, New JS, Daniell H. Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells. Plant Biotechnol J. 2013; 11:77–86.
34. D'Aoust MA, Couture MM, Charland N, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010; 8:607–619.
35. Future vaccine DARPA research. Arlingotn, VA: Defense Advanced Research Projects Agency;2012.